Elicio Therapeutics, Inc.
NASDAQ:ELTXBiotechnology
-$0.89 today
- Market cap
- $51.48M
- Beta
- 1.14
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$2.21
Volume 0.41M
Average 0.34M
Returns on capital
Elicio Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-2418.8%
avg -237.2%
ROIC
-201.0%
avg -69.9%
ROA
-153.0%
avg -119.7%
Analysis
ROA is currently the strongest return metric at -153.0% versus its period average of -119.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Robert T. Connelly | Chief Executive Officer, President & Director | USD 980.7K | 66 | — | — |
Christopher Haqq | Executive Vice President, Head of Research & Development and Chief Medical Officer | USD 750K | 60 | 64.64K | 0.34% |
Preetam Shah | Chief Strategy & Financial Officer and Treasurer | USD 687.08K | 53 | 60.83K | 0.32% |
Peter DeMuth | Chief Scientific Officer | USD 648.6K | 39 | 52.83K | 0.28% |
Allen Richard Nissenson FACP | Founder & Independent Director | USD 52.5K | 79 | — | — |
Esther Welkowsky | Senior Vice President of Clinical Development | — | — | — | — |
Megan C. Filoon | General Counsel, Secretary & Compliance Officer | — | — | — | — |
Darrell J. Irvine | Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board | — | — | — | — |
Joy Seymour | Vice President & Head of Regulatory Affairs | — | — | — | — |
Marc J. Wolfgang | Chief Technology Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Aug 29, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 16, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Elicio Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ELTX's management, answered from reported figures.
Who manages ELTX?
Elicio Therapeutics, Inc. (ELTX) lists 10 active executives. The top listed executive is Allen Richard Nissenson FACP, Founder & Independent Director.
Are ELTX insiders buying or selling?
Recent insider activity shows net buying of $38.43M.
Continue the stock analysis
Jump to another research area for this company.